Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session
The Deal Announces Candidates For Seventh Annual Most Admired Corporate Dealmakers Awards
Riding the Tech Roller Coaster
We crunch the numbers to see which stocks are most widely held among analyst-recommended large-cap funds.
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.